Screener
Tarsus Pharmaceuticals, Inc. TARS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s total equity?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total equity of $346.73M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total equity increased by 4.2% year-over-year, from $332.61M to $346.73M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s total equity has grown at a 15.7% compound annual growth rate (CAGR), from $165.98M to $343.43M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude